It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a drug atlas. The drug atlas represents the relations between drug effects and allows to identify independent processes for which the tumor might be particularly vulnerable when attacked by two drugs. Our approach enables the prediction of combination-therapy which can be linked to tumor-driving mutations. By using this strategy, we can uncover potential effective drug combinations on a pan-cancer scale. Predicted synergies are provided and have been validated in glioblastoma, breast cancer, melanoma and leukemia mouse-models, resulting in therapeutic synergy in 75% of the tested models. This indicates that we can accurately predict effective drug combinations with translational value.
Drug synergies impact the efficacy of combination therapies but are difficult to identify. Here Narayan et al. describe the drug atlas, a method to predict effective drug combinations from common exclusive drug effects providing a resource for exploring and understanding effective drug combinations.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details













1 Amsterdam UMC, location VUMC, Cancer Center, Department of Radiation Oncology, Amsterdam, the Netherlands
2 Academic Medical Center, Department of Oncogenomics, Amsterdam, the Netherlands (GRID:grid.5650.6) (ISNI:0000000404654431)
3 Massachusetts General Hospital and Harvard Medical School, Experimental Therapeutics and Molecular Imaging Lab, Neuroscience Center, Neuro-Oncology Unit, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
4 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.32224.35)
5 Netherlands Cancer Institute, Department of Psychosocial Research and Epidemiology, Amsterdam, the Netherlands (GRID:grid.430814.a)
6 Amsterdam UMC, location VUMC, Cancer Center, Department of Radiation Oncology, Amsterdam, the Netherlands (GRID:grid.430814.a)
7 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.430814.a)
8 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.430814.a); Amsterdam UMC, location VUMC, Cancer Center, Department of Medical Oncology, Amsterdam, the Netherlands (GRID:grid.430814.a)
9 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.430814.a); Amsterdam UMC, location VUMC, Cancer Center, Department of Hematology, Amsterdam, the Netherlands (GRID:grid.430814.a)
10 Amsterdam UMC, location AMC, Cancer Center, Center for Experimental Molecular Medicine (CEMM), Laboratory for Experimental Oncology and Radiobiology (LEXOR), Amsterdam, the Netherlands (GRID:grid.430814.a)
11 Amsterdam UMC, location VUMC, Department of Epidemiology and Biostatistics, Amsterdam, the Netherlands (GRID:grid.430814.a)
12 The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Division of Surgery, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
13 NYU Langone Health, Department of Radiation Oncology, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
14 The Jackson Laboratory for Genomic Medicine, Department of Computational Biology, Farmington, USA (GRID:grid.249880.f) (ISNI:0000 0004 0374 0039)
15 Kantonsspital Graubünden, Loëstrasse 170, Department of Radio-Oncology, Chur, Switzerland (GRID:grid.452286.f) (ISNI:0000 0004 0511 3514)
16 Academic Medical Center, Radiation Oncology, Amsterdam, the Netherlands (GRID:grid.5650.6) (ISNI:0000000404654431)
17 Amsterdam UMC, location AMC, Cancer Center, Center for Experimental Molecular Medicine (CEMM), Laboratory for Experimental Oncology and Radiobiology (LEXOR), Amsterdam, the Netherlands (GRID:grid.5650.6)
18 University of Birmingham, Edgbaston, Neurosurgery, Institute of Cancer and Genomic Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486)
19 IOTA Pharmaceuticals Ltd, St Johns Innovation Centre, Cowley Road, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
20 Amsterdam UMC, location VUMC, Cancer Center, Department of Radiation Oncology, Amsterdam, the Netherlands (GRID:grid.5335.0)
21 Amsterdam UMC, location VUMC, Cancer Center, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.5650.6)
22 Amsterdam UMC, location VUMC, Cancer Center, Department of Radiation Oncology, Amsterdam, the Netherlands (GRID:grid.5650.6)